imipenems

Imipenem is a broad-spectrum antibiotic belonging to the carbapenem class. It is administered intravenously and is often combined with cilastatin, a dehydropeptidase-I inhibitor. Cilastatin prevents the rapid renal excretion of imipenem, thereby increasing its concentration in the bloodstream and prolonging its therapeutic effect. This combination is effective against a wide range of Gram-positive and Gram-negative bacteria, including many strains resistant to other antibiotics.

The primary mechanism of action of imipenem involves the inhibition of bacterial cell wall synthesis. It binds to penicillin-binding proteins (PBPs), which are essential enzymes involved in the final stages of peptidoglycan cross-linking. By disrupting this process, imipenem weakens the bacterial cell wall, leading to cell lysis and death. Its broad spectrum makes it a valuable agent for treating serious infections such as pneumonia, intra-abdominal infections, urinary tract infections, and skin and soft tissue infections, particularly when caused by multidrug-resistant organisms.

Common side effects associated with imipenem/cilastatin therapy include gastrointestinal disturbances like nausea and vomiting, as well as injection site reactions. More serious adverse effects, though less common, can include seizures, hypersensitivity reactions, and potential for cross-reactivity with other beta-lactam antibiotics in patients with known penicillin allergies. Its use is generally reserved for situations where other antibiotic options are not suitable due to its potency and potential for resistance development.